This page is an index, not a new claim. Every figure it points at was opened, dated and graded on its own page first. What the index adds is the view across all of them at once — and that view produces a finding that the market's dosage charts cannot show, because showing it would break the chart.
The finding is that these numbers are not in the same units, and the differences are not cosmetic.
What the catalogue contains
Twenty-nine compounds and blends have a dated dose record on this site. Classified by the highest tier of source behind any figure on the page:
| Tier of best available source | Count | Compounds |
|---|---|---|
| 1 — FDA-approved label | 5 | semaglutide, tirzepatide, bremelanotide (PT-141), elamipretide (SS-31), tesamorelin |
| 2 — human study or registered protocol, no approval | 13 | NAD+, kisspeptin, retatrutide, cagrilintide, tesofensine, thymosin alpha 1, CJC-1295 (with DAC) and ipamorelin, DSIP, Semax, Selank, GHK-Cu (topical), BPC-157, Melanotan II |
| 4–5 — clinic, vendor or community convention only | 11 | 5-amino-1MQ, AOD-9604, IGF-1 LR3, KPV, TB-500, MOTS-c, epitalon, SLU-PP-332, KLOW, the Wolverine stack, Lipo-C |
The tier-2 row is the one to read carefully. It holds compounds with very different amounts of evidence behind the same grade. Thymosin alpha 1 has 66 registrations and 39 randomised trials. Kisspeptin has been infused into healthy volunteers, women with hypothalamic amenorrhoea, IVF patients and men with hypoactive sexual desire disorder, with the doses published to two decimal places. BPC-157's human record is one retrospective series of 12 knee injections with no control group. Melanotan II's is a single registration that has posted nothing. The tier describes the kind of source; only the compound's page describes how much of it exists.
The six units, and why the chart cannot be one number
Here is the obstacle, stated plainly. The dose records in this catalogue are published in at least six forms that do not convert into one another without information a vial label does not carry:
| Form the record takes | Example from this catalogue | What is missing before it becomes a quantity |
|---|---|---|
| Flat milligrams | Bremelanotide 1.75 mg per dose (Vyleesi label) | Nothing — this one is directly usable |
| Micrograms per kilogram | CJC-1295 with DAC, 30–60 mcg/kg | A body weight |
| Nanomoles per kilogram per hour | Kisspeptin-54, 1 nmol/kg/h intravenously | A body weight, a duration, and a molecular weight to reach mass |
| USP Units | Chorionic gonadotropin, 500–4,000 USP Units | A potency-to-mass relationship the vial states and the literature often does not |
| Percentage of a solution | Semax, published as a percentage of a nasal solution | A volume instilled |
| Micrograms per square metre | Thymosin alpha 1, 900 mcg/m² twice weekly | A body surface area, itself derived from height and weight |
| A share of a premixed vial | KLOW, 50/10/10/10 mg in one vial | The vial's ratio — one stated amount fixes the other components |
A chart with one number per compound has quietly supplied every missing value in the right-hand column — a weight, a duration, a surface area — and has not told the reader which values it chose. That is the mechanism by which a chart can be composed entirely of real published figures and still be wrong.
The widest spread inside a single molecule illustrates the same problem without leaving tier 1. Semaglutide is labelled in the US across two routes and five separate dose ladders. The lowest labelled figure is 0.25 mg once weekly; the highest is 25 mg once daily. Expressed per week, that is 0.25 mg against 175 mg — a 700-fold range, every point of it approved, for one active ingredient. "Semaglutide dose" is not a question with an answer until the product, the route and the indication are named.
How to use the index
Each row below links to the page that holds the full record: what was administered, to whom, by what route, in what study or under what label, with the dates and registrations. The pages report; they do not recommend, and none of the figures on them is offered as one to use.
Approved labels
- Semaglutide — four brand names, two routes, five dose ladders, and the label's own statement that two oral products are not interchangeable milligram for milligram.
- Tirzepatide — two brands at identical strengths with three different ceilings.
- PT-141 / bremelanotide — 1.75 mg subcutaneously, with two uses the label explicitly excludes.
- SS-31 / elamipretide — approved in 2025 as FORZINITY at 40 mg once daily; the one compound in this catalogue that moved from research market to label.
- Tesamorelin and sermorelin — a current label, a withdrawn one, and the compounding convention that filled the gap.
Human studies without approval
- Kisspeptin — a large, precise record in units no vial label uses.
- Retatrutide — every circulating figure traces to one trial's arm labels.
- Cagrilintide — 43 registrations, one sponsor, and most of them study it in combination.
- Tesofensine — twenty years of trials, four oral doses, no phase 3.
- Thymosin alpha 1 — the best-evidenced compound on FDA's withdrawn list.
- CJC-1295 and ipamorelin — two compounds with human studies, and a blend with none.
- DSIP — every human study used a vein; the market sells a needle.
- Semax — published figures are concentrations, not milligrams.
- Selank — two randomised papers in one journal.
- GHK-Cu — topical concentrations with trials, injectable figures without them.
- BPC-157 — one uncontrolled retrospective series, and a large body of convention.
- Melanotan II — one registration, which borrows its design from a programme it is not part of.
- NAD+ — a 10 mg randomised trial, a 500 mg wellness vial, and nothing connecting the two. Not a peptide.
No human dose record
- 5-Amino-1MQ — four papers, all in mice or cells.
- AOD-9604 — more published chemistry on detecting it than on what it does.
- IGF-1 LR3 — 44 papers, not one a human study.
- KPV — most of the research is about delivery, not dose.
- TB-500 — a fragment with no study of its own.
- MOTS-c — no completed trial, and one registration worth reading.
- Epitalon — the human studies cited for it were done with a different substance.
- SLU-PP-332 — sold as a tablet; its developers published that it is not orally available. Not a peptide.
Premixed blends
- KLOW — four peptides at a fixed 5:1:1:1, so one stated figure sets all four.
- Wolverine stack — both halves now registered, neither registration stating a dose.
- Lipo-C — two pharmacies' formulas under one name, four ingredients against eight. Not a peptide.
The field guide
- How to read a peptide dosing claim — units, routes, frequencies, and the six-tier grading this index applies.
What this index deliberately does not do
It does not average the figures, rank the compounds, or produce a recommended range for anything. Those operations all require the missing values in the table above, and supplying them silently is the defect this page exists to name.
It also does not treat absence as reassurance. Seven compounds here have no human dose record; that is a statement about what has been measured, not a statement about what is safe or unsafe. Where a compound has an approved label, the label is for a stated indication in a stated population, and a figure lifted out of that context stops being a labelled dose.
Anyone reading a dose figure anywhere — here or elsewhere — can apply the same test the dosing-claim guide sets out: what is the quantity and its unit, what route, what frequency, over what duration, and from what source. A figure that cannot answer all five is not yet a dose. Decisions about administering anything to a person belong with a clinician, and nothing on this page is offered in place of that.